GSK PLC GLAXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GLAXF is a good fit for your portfolio.
News
-
Moderna wins second product approval with RSV vaccine
-
AstraZeneca started at buy at Goldman, which rates GSK a neutral
-
Who will be the winner in Rishi Sunak's snap U.K. election?
-
GSK Says Illinois Jury Finds Heartburn Drug Zantac Not Liable for Plaintiff's Cancer
-
Moderna, CureVac, other vaccine stocks jump as new human bird-flu cases reported in U.S., Australia
-
Potential blockbuster asthma drug met goals in trials, GSK says
-
GSK's Potential Blockbuster Asthma Drug Shows Promise in Latest Trial — 2nd Update
-
GSK Potential Blockbuster Asthma Drug Shows Promise in Latest Trial — Update
Trading Information
- Previous Close Price
- $22.50
- Day Range
- $22.65–22.65
- 52-Week Range
- $16.65–23.00
- Bid/Ask
- $21.33 / $23.00
- Market Cap
- $92.37 Bil
- Volume/Avg
- 161 / 2,470
Key Statistics
- Price/Earnings (Normalized)
- 11.34
- Price/Sales
- 2.45
- Dividend Yield (Trailing)
- 3.28%
- Dividend Yield (Forward)
- 3.37%
- Total Yield
- 3.28%
Company Profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 70,200
- Website
- https://www.gsk.com
Competitors
Valuation
Metric
|
GLAXF
|
MRK
|
PFE
|
---|---|---|---|
Price/Earnings (Normalized) | 11.34 | 57.38 | 19.41 |
Price/Book Value | 5.36 | 7.81 | 1.71 |
Price/Sales | 2.45 | 5.16 | 2.85 |
Price/Cash Flow | 11.08 | 18.16 | 18.31 |
Price/Earnings
GLAXF
MRK
PFE
Financial Strength
Metric
|
GLAXF
|
MRK
|
PFE
|
---|---|---|---|
Quick Ratio | 0.57 | 0.68 | 0.58 |
Current Ratio | 0.87 | 1.25 | 0.91 |
Interest Coverage | 8.94 | 3.97 | 0.74 |
Quick Ratio
GLAXF
MRK
PFE
Profitability
Metric
|
GLAXF
|
MRK
|
PFE
|
---|---|---|---|
Return on Assets (Normalized) | 11.25% | 5.22% | 4.98% |
Return on Equity (Normalized) | 51.21% | 13.56% | 10.90% |
Return on Invested Capital (Normalized) | 22.40% | 8.29% | 7.28% |
Return on Assets
GLAXF
MRK
PFE
Drug Manufacturers - General Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Mlmdnbwb | Ryrhj | $779.7 Bil | |
JNJ
| Johnson & Johnson | Njtvfmpl | Smsjg | $347.6 Bil | |
MRK
| Merck & Co Inc | Gfscnjhm | Jsvmv | $319.4 Bil | |
ABBV
| AbbVie Inc | Fczzvpd | Fngcb | $284.7 Bil | |
AZN
| AstraZeneca PLC ADR | Kzdvftryt | Kzvcx | $236.8 Bil | |
NVS
| Novartis AG ADR | Vdqnrmmn | Pwg | $210.4 Bil | |
RHHBY
| Roche Holding AG ADR | Trdxblmwnf | Rcsx | $206.4 Bil | |
AMGN
| Amgen Inc | Zzhxhzmdl | Zczzg | $164.1 Bil | |
PFE
| Pfizer Inc | Qbqhhjtfp | Mnqp | $159.8 Bil | |
SNY
| Sanofi SA ADR | Vkhdtwds | Tzs | $121.5 Bil |